Is Draganfly's Army Partnership a Game-Changer for Investors?
Advanced Proteome Therapeutics
WKN: A2PJ6N / Name: Advanced / Aktie / Biotechnologie & medizinische Forschung / Micro Cap /
0,003 €
-
Is Draganfly's Army Partnership a Game-Changer for Investors?
On Sept. 30, the market delivered a powerful and unambiguous verdict on Draganfly Inc. (NASDAQ: DPRO). Shares of the drone technology company surged over 17%, driven by an unprecedented wave of
Dragonfly's U.S. Army contract is a major inflection point not just a short-term catalyst but a full-on strategic shift. The multi-layered deal (hardware, training, embedded manufacturing) gives them a sticky, long-term revenue stream and sets them apart from other small-cap drone players. Add in a strong cash position and NDAA-compliant supply chain, and they’ve got the tools to scale fast without dilution.
This isn’t just another defense contract — it’s a vote of confidence from the most demanding buyer in the world.
Neueste Beiträge
meoowu77 in Coats Group H1 Earnings Call Highlights